|Bid||0.0230 x 0|
|Ask||0.0250 x 0|
|Day's range||0.0220 - 0.0240|
|52-week range||0.0220 - 0.0740|
|Beta (5Y monthly)||2.18|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||23.00|
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challengeResults achieved statistical significance in post-hoc analysis of the full data set and in relevant subpopulations Favourable safety, tolerability and PK findings are consistent with a fast-acting non-sedating anxiolytic profileThe company is planning an End of Phase 2 (EoPh2) meeting to discuss BNC210’s late-stage SAD program 2H 2023 Webcast and conference call sch
Bionomics Limited Unsponsored ADR (BNOX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bionomics ( ASX:BNO ) First Half 2023 Results Key Financial Results Net loss: AU$16.2m (loss widened by 24% from 1H...